Skip to main content
Top
Published in: Tumor Biology 9/2015

01-09-2015 | Research Article

MicroRNA signatures in total peripheral blood of gallbladder cancer patients

Authors: Gangqiang Li, Yabin Pu

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that function as negative regulators of gene expression. Expression analysis of miRNAs can reflect the developmental lineage and differentiation state of the tumor. Thus, the miRNA profiles could play essential roles in gallbladder cancer (GBC). However, their role as novel biomarkers for the diagnosis of GBC is unclear yet. We assessed here for the first time whole-genome miRNA expression in peripheral blood samples of 40 GBC patients using microRNA microarray. We identified 11 miRNAs, which are significantly dysregulated in GBC patients in comparison to 40 healthy controls. Among these, the expression of let-7a, miR-21, miR-187, miR-143, miR-202, and miR-335 are in agreement with those measured by real-time PCR (p < 0.05). Furthermore, dysregulated miR-187, miR-143, and miR-202 demonstrate a significant correlation with clinicopathologic features (p < 0.05). Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
Literature
1.
go back to reference Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27(4):642–53.CrossRefPubMed Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27(4):642–53.CrossRefPubMed
2.
3.
4.
go back to reference Su M, Zhao X. Dignostic value of detection of CA19-9,CEA,AFP and CA125in gallbladder carcinoma patients. Med J PAPF. 2008;9(10):906–8. Su M, Zhao X. Dignostic value of detection of CA19-9,CEA,AFP and CA125in gallbladder carcinoma patients. Med J PAPF. 2008;9(10):906–8.
5.
go back to reference Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–93.CrossRefPubMed Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–93.CrossRefPubMed
6.
go back to reference Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. Plos One. 2008;3(9):3138–45.CrossRef Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. Plos One. 2008;3(9):3138–45.CrossRef
7.
go back to reference Huang Y, Shen XJ, Zou Q, et al. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67(1):129–39.CrossRefPubMed Huang Y, Shen XJ, Zou Q, et al. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67(1):129–39.CrossRefPubMed
8.
go back to reference Chan SH, Wu CW, Li AF, et al. mir-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 2008;28(2):907–11.PubMed Chan SH, Wu CW, Li AF, et al. mir-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 2008;28(2):907–11.PubMed
9.
go back to reference Michael MZ, O’Connor SM, Van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.PubMed Michael MZ, O’Connor SM, Van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.PubMed
10.
11.
go back to reference Yu F, Yao H, Zhu P, et al. Let-6 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.CrossRefPubMed Yu F, Yao H, Zhu P, et al. Let-6 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.CrossRefPubMed
12.
go back to reference Szafranska AE, Davision TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;28(26):4442–52.CrossRef Szafranska AE, Davision TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;28(26):4442–52.CrossRef
13.
go back to reference Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular cancinoma. J Clin Oncol. 2011;29(36):4781–8.CrossRefPubMed Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular cancinoma. J Clin Oncol. 2011;29(36):4781–8.CrossRefPubMed
14.
go back to reference Chao A, Lin CY, Lee YS, et al. Regulation of ovarian cancer progression by microRNa-187 through targeting disabled homolog-2. Oncogene. 2011;10(7):269–73. Chao A, Lin CY, Lee YS, et al. Regulation of ovarian cancer progression by microRNa-187 through targeting disabled homolog-2. Oncogene. 2011;10(7):269–73.
15.
go back to reference Song T, Zhang X, Wang C, et al. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev. 2011;12(4):929–33.PubMed Song T, Zhang X, Wang C, et al. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev. 2011;12(4):929–33.PubMed
16.
go back to reference Huang HY, Cheng YY, Liao WC, et al. SoX4 transcriptionally regulates multipleSEMA3/plexin family members and promotes tumor growth in pancreatic cancer. Plos One. 2012;7(12):48637–742.CrossRef Huang HY, Cheng YY, Liao WC, et al. SoX4 transcriptionally regulates multipleSEMA3/plexin family members and promotes tumor growth in pancreatic cancer. Plos One. 2012;7(12):48637–742.CrossRef
17.
go back to reference Zu Y, Ban J, Xia Z, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han population. Biochem Biophys Res Commun. 2013;430(2):529–34.CrossRefPubMed Zu Y, Ban J, Xia Z, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han population. Biochem Biophys Res Commun. 2013;430(2):529–34.CrossRefPubMed
18.
go back to reference Hu Y, Ou Y, Wu K, et al. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumor Biol. 2012;33(6):1863–70.CrossRef Hu Y, Ou Y, Wu K, et al. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumor Biol. 2012;33(6):1863–70.CrossRef
19.
go back to reference Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442–9.CrossRefPubMed Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442–9.CrossRefPubMed
20.
go back to reference Ma Y, Zhang P, Wang F, et al. Mir-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447–53.CrossRefPubMed Ma Y, Zhang P, Wang F, et al. Mir-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447–53.CrossRefPubMed
Metadata
Title
MicroRNA signatures in total peripheral blood of gallbladder cancer patients
Authors
Gangqiang Li
Yabin Pu
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3412-4

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine